A randomised, double blind, parallel group, multicentre trial comparing the efficacy and tolerability either of NOLVADEX or of ARIMIDEX or of Placebo in preventing the development (worsening) of gynecomastia in patients being treated with CASODEX 150 mg monotherapy for prostate cancer
Study identifier:7054IT/0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double blind, parallel group, multicentre trial comparing the efficacy and tolerability either of NOLVADEX or of ARIMIDEX or of Placebo in preventing the development (worsening) of gynecomastia in patients being treated with CASODEX 150 mg monotherapy for prostate cancer
Medical condition
prostate cancer
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Nov 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
